Loading...
XSHE300267
Market cap714mUSD
Jan 10, Last price  
2.54CNY
1D
-4.87%
1Q
-5.22%
Jan 2017
-80.54%
IPO
16.24%
Name

Hunan Er-Kang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300267 chart
P/E
—
P/S
2.94
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-5.41%
Revenues
1.78b
-4.67%
126,132,271157,832,491363,933,848608,416,476834,858,6441,010,838,0171,370,358,4911,737,940,0352,705,821,6232,827,885,1902,354,485,5792,744,341,0052,382,275,0102,235,302,7871,870,540,8101,783,118,780
Net income
-195m
L
10,844,11322,750,49066,462,150117,811,939151,906,924192,929,449288,288,645588,718,936795,403,732522,456,311216,579,339161,530,199192,306,417045,944,930-195,322,353
CFO
148m
-47.18%
209,79810,181,90742,471,66475,733,19284,021,539174,221,200175,382,420518,955,781486,495,536687,211,143123,894,781445,815,848178,527,34192,683,406281,019,942148,420,737
Dividend
Jun 09, 20230.03 CNY/sh
Earnings
May 16, 2025

Profile

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. The company was founded in 2003 and is based in Liuyang, China.
URL
https://www.hnerkang.com/
IPO date
Sep 27, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,783,119
-4.67%
1,870,541
-16.32%
Cost of revenue
1,841,453
1,660,159
Unusual Expense (Income)
NOPBT
(58,334)
210,381
NOPBT Margin
11.25%
Operating Taxes
22,921
Tax Rate
NOPAT
(81,255)
210,381
Net income
(195,322)
-525.12%
45,945
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
341,889
400,750
Long-term debt
2,335
5,153
Deferred revenue
18,386
23,148
Other long-term liabilities
1
Net debt
(651,762)
(547,734)
Cash flow
Cash from operating activities
148,421
281,020
CAPEX
(238,187)
Cash from investing activities
(117,726)
Cash from financing activities
(166,006)
FCF
(11,888)
6,261
Balance
Cash
744,468
878,786
Long term investments
251,517
74,851
Excess cash
906,829
860,110
Stockholders' equity
3,805,657
4,060,772
Invested Capital
4,264,627
4,613,764
ROIC
4.78%
ROCE
3.81%
EV
Common stock shares outstanding
2,062,538
2,062,605
Price
3.21
-9.58%
3.55
-25.11%
Market cap
6,620,747
-9.58%
7,322,247
-25.11%
EV
5,942,954
6,774,784
EBITDA
145,957
386,867
EV/EBITDA
40.72
17.51
Interest
6,664
5,502
Interest/NOPBT
2.62%